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Original Article
Ceftriaxone Potentiates Warfarin Activity
Greater Than Other Antibiotics in the
Treatment of Urinary Tract Infections
Lindsay M. Saum, PharmD, BCPS, CGP1,2,
and Ryan P. Balmat, PharmD, BCPS3
Abstract
Background: The cephalosporin class has been associated with an increased risk of bleeding among elderly patients receiving warfarin.
Urinary tract infections (UTI) are the most prevalent infection in elderly patients. Objective: To determine the extent of interaction
between antibiotics used in the treatment of UTI, particularly specific cephalosporins and warfarin. Methods: A retrospective chart
review was conducted on chronic warfarin patients with a diagnosis of UTI treated with ceftriaxone, a first-generation cephalos-
porin, penicillin, or ciprofloxacin. The primary outcome was the comparison of the extent of international normalized ratio (INR)
change from baseline between each antibiotic group. Results: The ceftriaxone group was found to have a statistically significant higher
peak INR value compared to all other studied antibiotics (ceftriaxone: 3.56, first-generation cephalosporins: 2.66, penicillins: 2.98,
ciprofloxacin: 2.3; P ¼ .004), a statistically significant greater extent of change in INR value (þ1.19, þ0.66, þ0.8, þ0.275;
P ¼ .006), and a statistically significant greater percentage change in INR value when compared to ciprofloxacin (54.4% vs 12.7%;
P¼ .037). Conclusion: Ceftriaxone interacts with warfarin to increase a patient’s INR value more than other commonly administered
antibiotics for UTI treatment. Other antibiotics should be preferred for UTI treatment in patients on warfarin.
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Introduction
Warfarin sodium is the most commonly used oral anticoagulant
in the treatment of deep venous thromboembolism, pulmonary
embolism, and ischemic cerebrovascular disease, and in the pre-
vention of thromboembolic complications in patients with atrial
fibrillation, chronic heart failure, and/ormechanical heart valves.1
Despite its longandwell-establisheduse,warfarin remains a com-
plicatedmedication for numerous reasons.Warfarin has a narrow
therapeutic index, has numerous drug and food interactions, and
displays significant inconsistency indose response based onmany
patient characteristics. Due to this, warfarin requires frequent
monitoring and dose alterations to minimize subtherapeutic and
supratherapeutic international normalized ratio (INR) values and
possible serious complications.
One frequent reason warfarin therapy can become subthera-
peutic or supratherapeutic is drug interactions.1-3 In a systema-
tic literature review of warfarin and its drug and food
interactions, many anti-infectives were described as having a
high probability of potentiating the effect of warfarin.2 This
interaction can occur via multiple mechanisms, with the 2 most
frequently cited being the inhibition of cytochrome p450
(CYP) isozymes, particularly CYP2C9 and CYP3A4, and the
disruption of intestinal normal flora. These interactions result
in decreased warfarin metabolism and reduction in organic
vitamin K synthesis respectfully, both contributing to increases
in INR values and a significant increase in bleeding risk.3,4
In a recent study by Baillargeon et al, it was found that any
anti-infective use was associated with a 2-fold increased risk of
bleeding within 15 days of anti-infective administration in
elderly chronic warfarin users.4 The authors determined that
the cephalosporin class was associated with the third highest
risk of bleeding, behind azole antifungals and sulfamethoxa-
zole/trimethoprim and ahead of fluoroquinolones. To date,
there are no studies showing a significant interaction between
cephalosporins and warfarin, and only case reports examined
such interactions.5 Currently, there is no literature examining
the bleeding risk and extent of interaction between specific
cephalosporins or generations of cephalosporins and concur-
rent warfarin use.
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Among elderly hospitalized patients (greater than or equal
to 65 years of age), urinary tract infections (UTIs) are the
most common infection diagnosed, accounting for 25% of all
infections in this population.4,6 Because the elderly are also
the largest demographic of warfarin users,1 the coadministra-
tion of warfarin and antibiotics for UTI treatment is quite
common and potential interactions could be overlooked.4,6
Cephalosporins, such as cefazolin, cephalexin, and ceftriax-
one, are frequently used for the treatment of UTI in our hos-
pital. Therefore, the objective of this study is to compare the
extent of interaction between concurrent warfarin use and
antibiotics for the treatment of UTI, most notably specific
agents within the cephalosporin class.
Methods
A retrospective chart review of patients was conducted at a
community teaching hospital between June 1, 2011, and
September 30, 2012. Patients were included in this study
if they were admitted as an adult inpatient, had a diagnosis
of UTI, and were receiving warfarin for any indication prior
to admission (based on the admission medication reconcilia-
tion). Patients less than 18 years of age, patients who were
not receiving warfarin prior to hospital admission, and
patients who had an active bleeding event at the time of
antibiotic initiation were excluded from this study.
Demographics and laboratory data on study participants col-
lected from the patient chart included patient’s age, weight,
gender, race, body mass index, indication for warfarin use, goal
INR range, INR values during extent of hospital stay, length of
hospital stay, alkaline phosphatase, serum creatinine, and crea-
tinine clearance.
Included patients were divided into 4 groups based on the
antibiotic used to treat the UTI: ceftriaxone, first-generation
cephalosporins (including cefazolin or cephalexin), penicillins
(including ampicillin/sulbactam, amoxicillin/clavulanate, or
piperacillin/tazobactam), or ciprofloxacin. If a patient’s anti-
biotic was changed during the course of treatment, due to sus-
ceptibility reports, physician preference, or other reasons, the
original antibiotic was used to define the patient’s treatment
group. INR values were recorded on the date of admission
(or earliest documented), date of antibiotic start, and date of
peak INR value during the length of stay. Total INR change and
percentage of change in INR value from day one of antibiotic
use to the peak INR value were compared for each study group.
Additionally, bleeding events, defined as gastrointestinal, cer-
ebrovascular, or other, were identified in each study group
through a chart note review.
Statistics
Repeat measures analysis of variance (ANOVA) was used to
determine if there was a significant difference in the primary
outcome among the different antibiotic groups. The Fisher’s
exact test was used to compare the incidence of bleeding rates
between the groups. To determine if there was a statistically
significant difference in patient characteristics between the
antibiotic groups, patient demographic variables and baseline
data were compared using the Bonferroni’s post hoc test in
ANOVA, Kruskal-Wallis test, Fisher’s exact test, and/or Pear-
son chi-square test, as appropriate. Continuous variables were
compared using the Kruskal-Wallis test and reported as a med-
ian and interquartile range (IQR). Statistical analysis was con-
ducted using SPSS 20.0 (IBM SPSS, Chicago, Illinois), and a
P value of <.05 was considered statistically significant.
Results
There were a total of 209 patients who were screened and found
to have a diagnosis of a UTI and were on warfarin at some point
during their hospital admission. From those 209 patients, a total
of 89 patients were excluded. There were 61 patients who were
excluded for a lack of active warfarin treatment before admis-
sion and 16 patients who had a diagnosis of a bleed before anti-
biotic administration. Additionally, 7 patients had to be
excluded due to a lack of laboratory data, and 5 patients were
excluded who were never started on an antibiotic during their
hospital stay. In total, there were 120 patients who met inclu-
sion criteria and were analyzed in the study: 27 were treated
with ceftriaxone, 14 with a first-generation cephalosporin, 57
with a penicillin, and 22 with ciprofloxacin.
Table 1 presents the demographics and baseline data of the
120 analyzed patients in the study. No demographics or base-
line data were found to have any statistical differences among
the 4 antibiotic treatment groups. Overall, the majority of
patients were on warfarin for atrial fibrillation and had a goal
INR therapeutic range of between 2 and 3. Before antibiotic
initiation, it was found that only 45.8% of all patients were
within their documented therapeutic range. Although not statis-
tically significant, the ceftriaxone group did have the highest
percentage of patients within therapeutic range at baseline at
55.6%. The median baseline INR value of the 120 patients was
found to be 1.97 (IQR 1.31-2.63).
The 4 different antibiotic treatment groups were also com-
pared for coadministration of other drug–drug interactions with
warfarin. These included strong CYP2C9 and CYP3A4 inhibi-
tors, selective serotonin reuptake inhibitors, selective norepi-
nephrine reuptake inhibitors, and corticosteroids. There was
not found to be any statistically significant differences between
the antibiotic treatment groups in the coadministration of addi-
tional interacting medications with warfarin that could have
confounded the results.
Table 2 displays the primary and secondary objective
patient data after antibiotic initiation for each of the antibiotic
treatment groups. Among all patients, the median number of
days from antibiotic initiation to peak INR value was 2 days
(IQR 1-3), and there was not found to be a statistically signif-
icant difference between any of the antibiotic treatment groups
in this aspect. The median peak INR value of all patients was
found to be 3.09 (IQR 2.08-4.1). When comparing the peak
INR values, the ceftriaxone treatment group had a statistically
significant higher peak when compared to the first-generation
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cephalosporins, penicillins, and ciprofloxacin treatment groups
(3.56, IQR 2.91-5.2; 2.66, IQR 1.79-3.75; 2.98, IQR 2.16-4.07;
2.3, IQR 1.87-3.34, respectively; P ¼ .004). The ceftriaxone
treatment group was also found to have a greater total increase
in INR value from baseline compared to all other antibiotic
treatment groups (1.19, IQR 0.82-2.45; 0.66, IQR 0.01-1.17;
0.8, IQR 0.13-1.5; 0.275, IQR 0-1.07, respectively; P ¼
.006). We also assessed the percentage of INR change from
baseline and found that the ceftriaxone treatment group had a
greater percentage change than all other treatment groups but
was only found to be statistically significant when compared
to ciprofloxacin (54.4 vs 12.7; P ¼ .037). Four bleeding events
were observed after antibiotic administration, all of which
occurred in the penicillin treatment group, but was not found
to have any statistical significance.
Discussion
Among the examined treatments for UTIs, ceftriaxone was the
most likely to significantly increase the INR value in chronic
warfarin patients. Presently, there is limited literature addres-
sing this interaction between ceftriaxone and warfarin, but our
finding is consistent with Clark et al’s report that ceftriaxone
may have a significant potentiating interaction with warfarin.5
The mechanism of interaction between ceftriaxone and war-
farin is currently not well defined. It is known, however, that
antibiotics can interfere with the normal intestinal flora that
produce a substantial amount of vitamin K. The recommended
daily allowance for vitamin K for adults is 90 mg.7 One small
study of health volunteers determined that approximately
1.6 mg of menaquinones (bacteria-synthesized vitamin K) were
produced by the colonic bacteria.8 Ceftriaxone undergoes an
estimated 33% to 67% biliary excretion, generating relatively
high concentrations in the intestine.9 This pharmacokinetic trait
provides ceftriaxone the ability to interfere with the intestinal
normal flora to a larger extent than primarily renally excreted
antibiotics, thus causing a greater reduction in the organic pro-
duction of vitamin K.
In this study, patients started on ciprofloxacin had the least
change in INR value. This finding could be considered contro-
versial considering some previous literature has described a
greater warfarin-potentiating effect of ciprofloxacin than
shown here. In a literature review by Holbrook et al, the authors
categorized ciprofloxacin as 1 of 8 anti-infectives with a highly
probable association with a warfarin-potentiating interaction.2
Conversely, a literature review by Carroll et al on potential
interactions between warfarin and 3 separate fluoroquinolones
concluded that ciprofloxacin did not display consistent
Table 2. Analyzed Results After Antibiotic Administration.
CTX CEF PCN CIP P value
Days to peak INR (IQR) 3 (1-5) 2 (0.75-3) 2 (1-5) 1.5 (.3-2.5) .138
Peak INR (IQR) 3.56 (2.91-5.2) 2.66 (1.79-3.75) 2.98 (2.16-4.07) 2.3 (1.87-3.34) .004
Total INR increase (IQR) 1.19 (0.82-2.45) 0.66 (0.01-1.17) 0.8 (0.13-1.5) 0.275 (0-1.07) .006
INR percentage changea (IQR) 54.4 (23.9-119) 39.6 (0.76-77.2) 42.8 (6.04-81.6) 12.7 (0-49.7) .037b
Bleed, % of patients 0 0 4 (8) 0 .526
Abbreviations: CTX, ceftriaxone; CEF, first-generation cephalosporins; PCN, penicillins; CIP, ciprofloxacin; INR, international normalized ratio; IQR, interquartile
range.
aPercentage change from baseline: ([peak INR value – baseline INR value] / baseline INR value)  100.
bStatistical significance only between ceftriaxone and ciprofloxacin.
Table 1. Demographics and Baseline Patient Data.
CTX CEF PCN CIP P value
Age, years 79 75 75 78 .939
Length of Stay, days 8 9 7 6 .366
Indication,a % of patients
Afib 59.3 57.1 48.1 33.3 .399
VTE 25.9 7.1 35.2 42.8
Heart valve 11.1 21.4 1.9 9.5
Goal INR,b % of patients
2-3 81.5 92.9 91.2 86.4 .684
2.5-3.5 7.4 7.1 3.5 13.6
Within TR, % of patients 55.6 35.7 49.1 31.8 0.322
INR at antibiotic initiation, (IQR) 2.3 (1.48-2.91) 1.83 (1.39-2.49) 1.92 (1.54-2.86) 1.82 (1.34-2.5) .603
Other warfarin interactive medications, % of patients 48.1 71.4 49.1 50 .484
Abbreviations: CTX, ceftriaxone; CEF, first-generation cephalosporins; PCN, penicillins; CIP, ciprofloxacin; AFib, atrial fibrillation; VTE, venous
thromboembolism; INR, international normalized ratio; TR, therapeutic range; IQR, interquartile range.
aRemaining percent ‘‘other.’’
bRemaining percent per physician preference.
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increases in anticoagulant effects during coadministration.10 In
view of these inconsistencies and the results of our study, this
relationship should be investigated further in future studies.
The results of this study may have been influenced by some
limitations. First, the study was a retrospective design, leaving
a greater opportunity that the results were due to chance. Sec-
ond, a greater than expected percentage of patients were not
within therapeutic INR range for warfarin therapy at baseline.
In consequence, changes in patients’ INR value, due factors
prior to admission such as recent changes in warfarin dose or
noncompliance, could have been attributed to attaining thera-
peutic range. It should be recognized, though, that the ceftriax-
one group did have the highest baseline INR and the greatest
percentage of patients within their therapeutic range at baseline
(2.3% and 55.6%, respectively). Therefore, this limitation most
likely did not have much effect on the significant INR increase
observed within the ceftriaxone group. Third, INR values were
not able to be collected after patient’s discharge from the hos-
pital. This limited the overall amount of data that were able to
be collected in our study. Furthermore, findings by Baillargeon
et al determined that any anti-infective coadministered with
warfarin therapy can increase a patient’s risk of bleeding for
at least 15 days.4 Our median length of stay was only 7 days;
therefore, additional warfarin potentiation could have been
missed in patients after discharge. Finally, warfarin dosing
changes were not included. Consequently, the intensity of
anticoagulation therapy and the occurrence of any dose
increases or reductions before antibiotic administration that
could have influenced INR value changes were not analyzed.
Conclusion
Utilization of any antibiotic has been shown to potentiate the
effect of warfarin, putting a patient at risk of bleeding events.
Based on our findings, clinicians should consider avoiding cef-
triaxone for the treatment of UTIs in chronic warfarin patients
and prescribe antibiotics with established lesser degree of
warfarin-potentiating effects. First-generation cephalosporins
could be recommended as a better option within the cephalos-
porin class as appropriate to regional susceptibility data. If such
therapeutic substitution is not possible, then close monitoring
of INR, both inpatient and outpatient, is warranted.
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